Russell Investments Group’s UroGen Pharma URGN Stock Holding History

Russell Investments Group’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.5M	Buy	94,979 +31,733	+50%	+$860K	﹤0.01%	1732
2026 Q1	$1.14M	Buy	63,246 +15,989	+34%	+$321K	﹤0.01%	2151
2025 Q4	$1.11M	Buy	47,257 +43,936	+1,323%	+$953K	﹤0.01%	2177
2025 Q3	$66.3K	Buy	3,321 +3,125	+1,594%	+$56.1K	﹤0.01%	3167
2025 Q2	$2.69K	Buy	+196	New	+$1.88K	﹤0.01%	3548
2024 Q4	–	Sell	-253	Closed	-$3.21K	–	3798
2024 Q3	$3.21K	Hold	253	–	–	﹤0.01%	3301
2024 Q2	$4.25K	Hold	253	–	–	﹤0.01%	3250
2024 Q1	$3.79K	Hold	253	–	–	﹤0.01%	2979
2023 Q4	$3.79K	Hold	253	–	–	﹤0.01%	2935
2023 Q3	$3.54K	Hold	253	–	–	﹤0.01%	3192
2023 Q2	$2.62K	Hold	253	–	–	﹤0.01%	3202
2023 Q1	$2.34K	Buy	+253	New	+$2.33K	﹤0.01%	2999
2022 Q3	–	Sell	-1,962	Closed	-$16K	–	2980
2022 Q2	$16K	Hold	1,962	–	–	﹤0.01%	2815
2022 Q1	$17K	Hold	1,962	–	–	﹤0.01%	2687
2021 Q4	$18K	Sell	1,962 -55,035	-97%	-$776K	﹤0.01%	2955
2021 Q3	$958K	Buy	56,997 +121	+0.2%	+$1.92K	﹤0.01%	2207
2021 Q2	$867K	Buy	56,876 +22,923	+68%	+$414K	﹤0.01%	2379
2021 Q1	$660K	Sell	33,953 -23,268	-41%	-$494K	﹤0.01%	2404
2020 Q4	$1.03M	Buy	+57,221	New	+$1.2M	﹤0.01%	2103
2018 Q4	–	Sell	-2,523	Closed	-$119K	–	3038
2018 Q3	$119K	Buy	+2,523	New	+$117K	﹤0.01%	2736

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Russell Investments Group's URGN Position: Q2 2026 in Review

Russell Investments Group increased its UroGen Pharma (URGN) stake by 50% in Q2 2026, buying an estimated $860K and bringing the position to 94,979 shares worth $3.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1732.

Russell Investments Group first reported a position in URGN in Q3 2018 and has held it in 20 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Russell Investments Group held 94,979 shares of UroGen Pharma worth $3.5M as of Q2 2026.
Russell Investments Group bought 31,733 UroGen Pharma shares in Q2 2026, an estimated $860K.
UroGen Pharma made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1732 holding.
Russell Investments Group first reported a position in UroGen Pharma in Q3 2018 and has held it in 20 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.